Accessibility Menu
Lyell Immunopharma logo

Lyell Immunopharma(NASDAQ) LYEL

Market Cap$317.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-96%
5 Year-96%
1 Year+10%
1 Month-0%
$12.88
-0.46%
-0.06Today
After hours$12.90+$0.02 (+0.16%)
Lyell Immunopharma last closing stock price
MetricPriceDate
Last closeUSD 12.942026-07-31
Lyell Immunopharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.45%USD 12.632026-07-24
1 month-0.23%USD 12.972026-07-01
3 month-37.88%USD 20.832026-05-01
Year to date-57.96%USD 30.782025-12-31
1 year+9.57%USD 11.812025-07-31
3 year-76.81%USD 55.802023-08-01
5 year-95.54%USD 290.002021-07-30
Since inception-96.17%USD 337.802021-06-17

Lyell Immunopharma Financials at a Glance

Market Cap

$317.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$31.00K

Net Income (TTM)

-$246.41M

EPS (TTM)

-$12.74

P/E Ratio

-1.02

Dividend

$0.00

Beta (Volatility)

1.61 (High)

Price

$12.88

Volume

67,589.362

Open

$13.05

Previous Close

$12.94

Daily Range

$12.71 - $13.15

52-Week Range

$9.28 - $45.00

Estimated Earnings Date

Aug 11, 2026

LYEL News

Doctor with senior man_GettyImages-1147479334

Why Shares of Lyell Immunopharma Jumped This Week

James HalleyJun 16, 2023

LYEL: Motley Fool Moneyball Superscore

50

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lyell Immunopharma

Lyell makes treatments that help immune cells fight cancer. These therapies target difficult tumors that standard medicines cannot reach. They focus on making immune cells stronger and longer-lasting.

Engineering Better Cancer Fighters

  • Ronde-cel: Dual-targeting therapy for blood cancers like large B-cell lymphoma; uses specialized engineering to target two different markers on cancer cells.
  • LYL273: Treatment for advanced colon cancer; engineered to help immune cells enter and survive inside tough tumor environments.
  • Research Pipeline: Programs targeting various other cancers using genetic tools to prevent immune cells from becoming tired while fighting.

Growing Through Strategic Moves

  • Acquired ImmPACT Bio USA Inc. in October 2024 to secure the ronde-cel therapy program.
  • Entered a license agreement with Innovative Cellular Therapeutics in November 2025 for solid tumor treatments.
  • Began patient dosing for the PiNACLE-H2H Phase 3 clinical trial in February 2026.
  • Built the LyFE Manufacturing Center in Washington to manage the production of its living medicines.

Why Lyell Stands Out

Lyell uses proprietary technologies to prevent immune cells from becoming exhausted while attacking tumors. Its dedicated manufacturing facility in Washington allows the company to produce more than 1,200 therapies per year.

Measuring Financial Progress

  • Revenue was $6,000 in Q4 2025, down 45.5% from $11,000 in Q4 2024.
  • Operating income hit -$62 million in Q4 2025, an improvement of 69.2% from Q4 2024.
  • Net income reached -$140.7 million in Q4 2025, which deepened from -$52.9 million in Q4 2023.
  • Free cash flow hit -$61.2 million in Q4 2025, worsening 29.4% from Q4 2024.

Bottom Line

Lyell has evolved from a researcher into a clinical-stage company with multiple therapies in human testing. Its strategy combines internal manufacturing with targeted acquisitions to improve how immune cells destroy cancer cells.

AI Generated • May 6, 2026

Industry

Biotechnology

Sector

Health Care

Employees

161

CEO

Lynn Seely, MD

Website

www.lyell.com

Headquarters

South San Francisco, CA 94080, US

LYEL Financials

Key Financial Metrics (TTM)

Gross Margin

-7422.58%

Operating Margin

-618909.68%

Net Income Margin

-794858.06%

Return on Equity

-85.71%

Return on Capital

-68.11%

Return on Assets

-70.28%

Earnings Yield

-98.04%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$317.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

24.50M

Volume

67.59K

Avg. Volume

160.18K

Financials (TTM)

Gross Profit

-$2.30M

Operating Income

-$191.86M

EBITDA

-$238.99M

Operating Cash Flow

-$133.80M

Capital Expenditure

-$623.00K

Free Cash Flow

-$134.42M

Cash & ST Invst.

$254.02M

Total Debt

$48.85M

Lyell Immunopharma Performance Analysis

Lyell Immunopharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 84,683,000695.1%
20232023-12-31USD 130,000-99.8%
20242024-12-31USD 61,000-53.1%
20252025-12-31USD 36,000-41.0%
Lyell Immunopharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3014.3%
Q32025-09-3087.5%
Q42025-12-31-60.0%
Q12026-03-31-66.7%
Lyell Immunopharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -14.82-28.1%
20232023-12-31USD -18.7026.1%
20242024-12-31USD -26.2340.3%
20252025-12-31USD -16.06-38.8%
Lyell Immunopharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-1505.6%
Q32025-09-3026.3%
Q42025-12-31-210.8%
Q12026-03-3183.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$2.00K

-71.4%

Gross Profit

-$2.33M

-33385.7%

Gross Margin

-1165.00%

N/A

Market Cap

$317.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.97M

N/A

Employees

161

N/A

Net Income

-$24.15M

+53.7%

EBITDA

-$21.82M

+55.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$254.02M

-15.7%

Total Debt

$48.85M

-14.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$39.49M

-19.2%

Short Term Debt

$9.36M

+13.7%

Return on Assets

-70.28%

N/A

Return on Invested Capital

-61.17%

N/A

Free Cash Flow

-$38.60M

+29.8%

Operating Cash Flow

-$38.51M

+29.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AMRNAmarin Corporation plc
$14.14-0.84%
EDITEditas Medicine, Inc.
$2.65+2.71%
ACIUAC Immune S.A.
$2.22+1.37%
LRMRLarimar Therapeutics, Inc.
$3.98+4.19%

Trending Stocks

Symbol / CompanyPricePrice Chg
SQQQProShares Trust - ProShares UltraPro Short Qqq
$41.33-0.05%
NVDANvidia
$207.17+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.80+0.07%
INTCIntel
$90.98+0.01%

Questions About LYEL

What is the current price of Lyell Immunopharma?

Lyell Immunopharma is trading at $12.87 per share.

What is the 52-week range for Lyell Immunopharma?

Over the past 52 weeks, Lyell Immunopharma has traded between $9.28 and $45.00.

How much debt does Lyell Immunopharma have?

As of the most recent reporting period, Lyell Immunopharma reported total debt of $48.85M.

How much cash does Lyell Immunopharma have on hand?

Lyell Immunopharma reported $90.77M in cash and cash equivalents in its most recent financial results.

What is Lyell Immunopharma’s dividend yield?

Lyell Immunopharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services